Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome and Chidamide in R/R PTCL
NCT05527275Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University. Primary endpoints: Recommended Phase II Dose at 24 months and Overall Response Rate at 24 months. Status: unknown.
02
Drugs
mitoxantrone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05527275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527275.